Medicenna Therapeutics Corp.
MDNAF
$0.8252
$0.03374.26%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.36% | -46.17% | -8.69% | -23.09% | -25.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.86% | 34.28% | 4.17% | -0.03% | -11.05% |
| Operating Income | -34.86% | -34.28% | -4.17% | 0.03% | 11.05% |
| Income Before Tax | -34.01% | 108.02% | -1.37% | -9.99% | -24.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.01% | 108.02% | -1.37% | -9.99% | -24.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.01% | 108.02% | -1.37% | -9.99% | -24.75% |
| EBIT | -34.86% | -34.28% | -4.17% | 0.03% | 11.05% |
| EBITDA | -34.56% | -34.17% | -4.13% | 0.12% | 11.14% |
| EPS Basic | -19.67% | 107.16% | 9.52% | 0.50% | -17.97% |
| Normalized Basic EPS | -19.47% | 107.13% | 9.45% | 0.40% | -18.32% |
| EPS Diluted | -19.67% | 107.16% | 9.52% | 0.50% | -17.97% |
| Normalized Diluted EPS | -19.47% | 107.13% | 9.45% | 0.40% | -18.32% |
| Average Basic Shares Outstanding | 12.09% | 12.28% | 12.02% | 10.34% | 5.72% |
| Average Diluted Shares Outstanding | 12.09% | 12.28% | 12.02% | 10.34% | 5.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |